2026/9/19 On behalf of Tianjin Chase Sun Jiandakang, PTS Phase II HCC trial abstract in China accepted for presentation at ESMO Asia 2026.

1.Date of occurrence of the event:2026/09/19

2.Company name:Gongwin Biopharm Holdings Co., Ltd.

3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):subsidiariese

4.Reciprocal shareholding ratios:80.91%

5.Cause of occurrence: Subsidiary Tianjin Hongri Jiandakang Pharmaceutical Technology Co., Ltd. (”Tianjin Hongjian”) announced that its study abstract on para-toluenesulfonamide (PTS) combined with transcatheter arterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC) in a Phase II clinical trial in China has been officially accepted for presentation at the ESMO Asia Congress 2026. The abstract will be presented as an electronic poster (ePoster) at the congress to be held in Singapore from December 4 to 6, 2026. The accepted abstract is numbered #1203 and entitled: ”Phase II trial of para-toluenesulfonamide (PTS), a novel liquid intratumoral ablative agent, plus TACE in unresectable HCC.” According to the congress notification, the abstract will be published in the ESMO Asia Congress 2026 Abstract Book and included in a supplement of the official ESMO journal, Annals of Oncology. This study is a single-arm Phase II clinical trial (CTR20132279) that enrolled a total of 20 patients with unresectable HCC, of whom 18 were evaluable for efficacy. According to mRECIST assessment, the confirmed complete response (CR) rate was 28% (5/18), the objective response rate (ORR) was 89% (16/18), and the disease control rate (DCR) was 100%. Thirteen patients (72%) showed >=75% tumor necrosis on contrast- enhanced imaging. In terms of safety, all observed adverse events were Grade 1-2, and no serious adverse events (SAEs) were observed.

6.Countermeasures:None

7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The development of new drugs is a lengthy and costly process, and there is no no guarantee of success. These factors may expose investments to risks. Investors should carefully assess the risks and exercise caution when making investments.